drugset / Trial / NCT02886715

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT02886715

Phase 3 Completed 1110 enrolled Fougera Pharmaceuticals Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Timeline

Start
2016-09-21
Primary completion
2017-05-31
Completion
2017-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tazarotene Small molecule 0.1 % Topical

Indications